GlassScriptPhysician profile
Clifton Allred
NPI 1265030175
$4,714.39
in general payments reported to CMS, 2019-2025
23 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $870 · 2022: $2,111 · 2023: $939 · 2024: $363 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,158.65 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $594.39 | 2021-2025 | Caplyta |
| Alkermes, INC. | $399.10 | 2021-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $376.51 | 2021-2025 | Rexulti |
| Lundbeck LLC | $286.21 | 2021-2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $239.66 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $226.46 | 2023-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $226.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.24 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $149.56 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $132.64 | 2023-2025 | Auvelity |
| Indivior INC. | $118.88 | 2022 | |
| Supernus Pharmaceuticals, INC. | $105.45 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $98.71 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $87.81 | 2023-2025 | Quviviq, Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $86.38 | 2021-2025 | Fanapt |
| Bausch Health US, LLC | $53.62 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $49.58 | 2022 | |
| Corium, LLC | $43.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.42 | 2024 | Cobenfy |
| Noven Therapeutics, LLC | $23.96 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.59 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.